HK1257240A1 - 預防和治療脂肪異常沉積導致的組織損傷的藥物及其用途 - Google Patents

預防和治療脂肪異常沉積導致的組織損傷的藥物及其用途

Info

Publication number
HK1257240A1
HK1257240A1 HK18116276.1A HK18116276A HK1257240A1 HK 1257240 A1 HK1257240 A1 HK 1257240A1 HK 18116276 A HK18116276 A HK 18116276A HK 1257240 A1 HK1257240 A1 HK 1257240A1
Authority
HK
Hong Kong
Prior art keywords
medicine
preventing
tissue injury
injury caused
treating tissue
Prior art date
Application number
HK18116276.1A
Other languages
English (en)
Inventor
李季男
Original Assignee
深圳瑞健生命科學研究院有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳瑞健生命科學研究院有限公司 filed Critical 深圳瑞健生命科學研究院有限公司
Publication of HK1257240A1 publication Critical patent/HK1257240A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18116276.1A 2016-12-15 2018-12-19 預防和治療脂肪異常沉積導致的組織損傷的藥物及其用途 HK1257240A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611162237 2016-12-15
CN201611161347 2016-12-15

Publications (1)

Publication Number Publication Date
HK1257240A1 true HK1257240A1 (zh) 2019-10-18

Family

ID=62656680

Family Applications (7)

Application Number Title Priority Date Filing Date
HK18116275.2A HK1257239A1 (zh) 2016-12-15 2018-12-19 預防和治療肥胖症的藥物及其用途
HK18116270.7A HK1257234A1 (zh) 2016-12-15 2018-12-19 治療冠狀動脈粥樣硬化及其併發症的藥物及其用途
HK18116269.0A HK1257233A1 (zh) 2016-12-15 2018-12-19 預防動脈粥樣硬化及其併發症的藥物及其用途
HK18116276.1A HK1257240A1 (zh) 2016-12-15 2018-12-19 預防和治療脂肪異常沉積導致的組織損傷的藥物及其用途
HK18116272.5A HK1257236A1 (zh) 2016-12-15 2018-12-19 預防和治療高脂血症的藥物及其用途
HK18116273.4A HK1257237A1 (zh) 2016-12-15 2018-12-19 預防和治療脂肪肝的藥物及其用途
HK18116702.5A HK1257583A1 (zh) 2016-12-15 2018-12-28 預防和治療脂肪代謝紊亂及其相關病症的藥物及其用途

Family Applications Before (3)

Application Number Title Priority Date Filing Date
HK18116275.2A HK1257239A1 (zh) 2016-12-15 2018-12-19 預防和治療肥胖症的藥物及其用途
HK18116270.7A HK1257234A1 (zh) 2016-12-15 2018-12-19 治療冠狀動脈粥樣硬化及其併發症的藥物及其用途
HK18116269.0A HK1257233A1 (zh) 2016-12-15 2018-12-19 預防動脈粥樣硬化及其併發症的藥物及其用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
HK18116272.5A HK1257236A1 (zh) 2016-12-15 2018-12-19 預防和治療高脂血症的藥物及其用途
HK18116273.4A HK1257237A1 (zh) 2016-12-15 2018-12-19 預防和治療脂肪肝的藥物及其用途
HK18116702.5A HK1257583A1 (zh) 2016-12-15 2018-12-28 預防和治療脂肪代謝紊亂及其相關病症的藥物及其用途

Country Status (2)

Country Link
CN (8) CN108210895A (zh)
HK (7) HK1257239A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108671226A (zh) * 2018-08-08 2018-10-19 广州铭康生物工程有限公司 有效治疗中心静脉导管并发症的药物及其用途
CN110093412A (zh) * 2019-03-29 2019-08-06 南方医科大学南方医院 用于诊断动脉粥样硬化的分子标志物ugp2及应用
CN111100928A (zh) * 2020-01-09 2020-05-05 武汉科技大学 动脉粥样硬化生物标志物及动脉粥样硬化诊断试剂盒
CN115551534A (zh) * 2020-02-26 2022-12-30 泰伦基国际有限公司 一种预防和治疗血压异常病症的方法和药物
CN112305120B (zh) * 2020-10-30 2022-02-08 河北医科大学第二医院 代谢物在动脉粥样硬化性脑梗死中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1408431A (zh) * 2001-09-21 2003-04-09 北京华兴生生物技术有限公司 治疗与新生血管生成相关疾病的基因工程药物
MXPA04007585A (es) * 2002-02-06 2005-09-20 N Zyme Biotec Gmbh Metodo para la produccion de proteinas recombinantes en microorganismos.
EP1509236A4 (en) * 2002-05-13 2008-07-30 Children S Hospital Los Angele TREATMENT AND PREVENTION OF ABNORMAL SCALING IN KELOIDS AND OTHER SKIN OR INTERNAL WOUNDS OR LESIONS
CN100446772C (zh) * 2002-12-06 2008-12-31 法布罗根股份有限公司 一种稳定HIFα的制剂在制备治疗糖尿病的药物中的应用
US7056943B2 (en) * 2002-12-10 2006-06-06 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
WO2005026127A1 (ja) * 2003-09-11 2005-03-24 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター－１阻害剤
DK1740698T3 (da) * 2004-04-22 2010-10-25 Talecris Biotherapeutics Inc Rekombinant modificeret plasmin
WO2006095713A1 (ja) * 2005-03-08 2006-09-14 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター－１阻害剤
JPWO2007111242A1 (ja) * 2006-03-24 2009-08-13 ロート製薬株式会社 メタボリック症候群改善剤
DK2056864T3 (en) * 2006-08-28 2014-03-10 Omnio Healer Ab CANDIDATES AGAINST INFECTION
MX2009004143A (es) * 2006-10-20 2009-11-26 Dow Global Technologies Inc Usos de derivados de celulosa solubles en agua para prevenir o tratar sindrome metabolico.
CN101842093B (zh) * 2007-10-23 2012-08-22 株式会社医药分子设计研究所 Pai-1产生抑制剂
US20090239868A1 (en) * 2007-10-23 2009-09-24 Institute Of Medical Molecular Design, Inc. Inhibitor of pai-1 production
RU2564131C2 (ru) * 2009-07-10 2015-09-27 ТромбоДженикс НВ Варианты плазминогена и плазмина
US20110039766A1 (en) * 2009-08-12 2011-02-17 Szeto Hazel H Methods for preventing or treating metabolic syndrome
WO2011139974A2 (en) * 2010-05-03 2011-11-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
BR112013017172A2 (pt) * 2011-01-05 2016-10-11 Thrombogenics Nv variantes de plasminogênio e plasmina
KR20140010126A (ko) * 2011-03-03 2014-01-23 터서스 파마수티칼 엘엘씨 C16:1n7-팔미톨리에이트를 포함하는 조성물들 및 방법들
CN102188699A (zh) * 2011-05-06 2011-09-21 南京农业大学 一种治疗动脉粥样硬化的药物组合物及其制备方法和应用
WO2013024074A1 (en) * 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
CN102532326B (zh) * 2011-11-18 2017-06-09 南京大学 一种肿瘤靶向的人纤溶酶原Kringle5变体及其应用
PE20160244A1 (es) * 2013-08-13 2016-05-10 Sanofi Sa Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos
US20160199466A1 (en) * 2013-08-20 2016-07-14 Trustees Of Dartmouth College Methods For Treating Tissue Fibrosis

Also Published As

Publication number Publication date
HK1257236A1 (zh) 2019-10-18
HK1257583A1 (zh) 2019-10-25
CN108210896A (zh) 2018-06-29
CN108210898A (zh) 2018-06-29
CN108210904A (zh) 2018-06-29
HK1257237A1 (zh) 2019-10-18
CN108210895A (zh) 2018-06-29
HK1257239A1 (zh) 2019-10-18
CN108210906A (zh) 2018-06-29
HK1257234A1 (zh) 2019-10-18
CN108210900A (zh) 2018-06-29
CN108210914A (zh) 2018-06-29
HK1257233A1 (zh) 2019-10-18
CN108210902A (zh) 2018-06-29

Similar Documents

Publication Publication Date Title
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
IL298689B1 (en) Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions
PT3377637T (pt) Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele
HK1257240A1 (zh) 預防和治療脂肪異常沉積導致的組織損傷的藥物及其用途
HK1257321A1 (zh) 用於治療腦組織的組織摧毀術治療系統和方法
HK1256721A1 (zh) 用於治療眼部病症的化合物和組合物
IL281585B (en) Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use
HK1257585A1 (zh) 預防和治療皮膚纖維化的藥物及其用途
GB201519557D0 (en) Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
IL272097A (en) Compounds for the prevention and treatment of medical disorders and their uses
IL269698B (en) Methods for preventing or treating eye diseases
EP3723742C0 (fr) Utilisation de la fluoroethylnormemantine pour la prevention et le traitement de l'anxiete
IL248935A0 (en) Diagnostic testing and treatment/prevention of Alzheimer's disease
HK1257238A1 (zh) 預防和治療脂質腎損傷的藥物及其用途
GB201522329D0 (en) Use of adjuvants for the prevention and/or treatment of autoimmune diseases
HK1257590A1 (zh) 預防和治療藥物性腎損傷的藥物及其用途
ZA201807692B (en) New use of product for skin treatment
IL256919A (en) Pharmaceutical compositions useful for the treatment of tissue damage
IL251135A (en) A method for the synthesis of hydroxy-triglycerides and their use for disease prevention and treatment
PT3191112T (pt) Compostos de dipeptidilcetoamida e sua utilização para o tratamento e/ou prevenção da acumulação de gordura
IL259381B (en) Miravegron for the treatment of retinal diseases
RS65225B1 (sr) Lek za lečenje i/ili prevenciju endometrioze
GB201604359D0 (en) Treatment of tissue disorders
ZA201904327B (en) Treatment of skin conditions
IL274132A (en) Treatment of skin problems